• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

0
  • by alexperjescuadmin
  • in Oncology
  • — 14 Dec, 2007
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
AudioMedica News
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide
00:00 /
RSS Feed
Share
Link
Embed
Stephen Jones
Stephen Jones

STEPHEN JONES, US Oncology Research, Houston
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.



LISTEN

[audio:https://www.audiomedica.com/podcasting/oncology/071213_stephen_jones.mp3]

Share

Tags: breast cancer survivalbreast-cancercyclophosphamidedocetaxeldoxorubiciniphoneOncologyoncology researchstephen jonessurvival advantagesurvival benefittaxanethorneus oncology

You may also like...

  • Multi-Gene Assays Now Recommended To Refine Chemotherapy Decisions in Breast Cancer Multi-Gene Assays Now Recommended To Refine Chemotherapy Decisions in Breast Cancer 15 Apr, 2009
  • Double Mastectomy: No Survival Gain for BRCA2 Mutation Carriers—AUDIO JOURNAL OF ONCOLOGY Double Mastectomy: No Survival Gain for BRCA2 Mutation Carriers—AUDIO JOURNAL OF ONCOLOGY 30 Mar, 2018
  • Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer 1 Oct, 2007
  • Kristin De Bruijn Diabetes increases risk of breast and colon cancer 4 Oct, 2013

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Live Report from ASH:
    Ibritumomab Provides Benefit in Patients with Follicular Lymphoma
  • Next story AACR In New Partnership For San Antonio Breast Cancer Symposium
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Brachytherapy “Excellent” After Breast…
    • PD-L1 Immunotherapy Delayed Triple Negative Breast…
  • Home
  • Oncology
  • Early Breast Cancer: Survival Benefit For Adjuvant Docetaxel/Cyclophosphamide

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.